AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01695044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
Study NCT03556059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role of EOSS
Description: The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
Study NCT02274116 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM - Intermittent Room Air - room air mixture
Description: Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
Study NCT02274116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
Study NCT01245699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
Description: scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
Study NCT03444298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Tocopherol
Description: Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
Study NCT03444298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gamma Tocopherol
Description: Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
Study NCT02278042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Consumption
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 6
Description: Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 12
Description: Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 18
Description: Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT00677807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Study NCT03444298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each dose consists of two capsules by mouth once daily for a total of 7 days.
Study NCT03444298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each dose consists of two capsules by mouth once daily for a total of 7 days.
Study NCT03458416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT02942771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.075mg/kg TT301/MW189
Description: 0.075 mg/kg IV twice daily on Days 1 through 5
Study NCT03397342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP machine
Description: Use of CPAP machine during MRI
Study NCT02546492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar gel
Description: Administration of the study drug in addition to the current maintenance immunosuppressive agents
Study NCT02942771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15mg/kg TT301MW189
Description: 0.15 mg/kg IV twice daily on Days 1 through 5
Study NCT02942771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg/kg TT301/MW189
Description: 0.25 mg/kg IV twice daily on Days 1 through 5
Study NCT02942771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.30mg/kg TT301/MW189
Description: 0.30 mg/kg IV twice daily on Days 1 through 5
Study NCT02942771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02423707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard Birch and/or 5-grasses
Description: 3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use.
Study NCT02423707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Description: This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
Study NCT04114279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Performance of laparoscopic duodenal atresia repair
Description: completion of laparoscopic duodenal atresia repair in a surgical simulator
Study NCT06200818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser
Study NCT06200818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:CrYSGG
Study NCT06200818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Study NCT01199302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered intravenously once every 4 weeks
Study NCT00318591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: hydrophilic coated urinary intermittent catheter
Study NCT00318591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conveen Uncoated
Description: Uncoated urinary intermittent catheter
Study NCT01184755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
Study NCT01184755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRate
Study NCT03754166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Description: Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom.
Study NCT02779127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical interrogatory
Description: Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
Study NCT02779127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical examination
Description: Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
Study NCT02779127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specific bioassay
Description: Exhaled carbon monoxide measure and nicotine in the urine are evaluated
Study NCT02779127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial function evaluation
Description: Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
Study NCT02779127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General bioassay
Description: Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
Study NCT02249156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Financial incentive for choosing a lower-cost provider
Description: Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
Study NCT04798560 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
Study NCT03028649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: β-hydroxy-β-methylbutyrate and a placebo supplementation
Study NCT03028649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate and a placebo supplementation
Study NCT05342870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
Study NCT00640497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IT-Combination
Description: The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
Study NCT03968835 — intervention group
Intervention type: OTHER
Intervention: Bacitracin
Description: For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
Study NCT03188276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir-Sofosbuvir
Description: 15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
Study NCT03188276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir-Sofosbuvir
Description: 17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
Study NCT00334893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT01836900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Description: Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
Study NCT01836900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hemostasis
Description: Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
Study NCT03968835 — intervention group
Intervention type: OTHER
Intervention: Skin Graft
Description: For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
Study NCT02652156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
Study NCT02652156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel®
Description: 20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
Study NCT02652156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
Study NCT00342849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succimer
Description: Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
Study NCT00342849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02265718 — intervention group
Intervention type: DRUG
Intervention: Ritalin
Description: 1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
Study NCT02265718 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: 1 - matching tablet taken once on Day 0 and once on Day 28
Study NCT00038571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS341 (Bortezomib)
Description: 1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
Study NCT02357394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin Pessary
Description: Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
Study NCT03552172 — intervention group
Intervention type: OTHER
Intervention: Physical activity
Description: PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
Study NCT03552172 — intervention group
Intervention type: OTHER
Intervention: Absence of or suspended physical activity
Description: the brakes responsible for a stop or lack of practice
Study NCT03775642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention video
Description: The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
Study NCT03775642 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control video
Description: The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
Study NCT04087733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZODROP
Description: 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
Study NCT00677807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Study NCT02319538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy performed
Description: Surgery combined with standard thyroxine treatment
Study NCT02012595 — intervention group
Intervention type: OTHER
Intervention: [11C]donepezil PET
Description: Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
Study NCT03160053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
Study NCT00983580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT00983580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Given PO
Study NCT00983580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study
Study NCT00983580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative study
Study NCT00983580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00983580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Ancillary studies
Study NCT00983580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Ancillary studies
Study NCT01482767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon Alfa 2b (PEG-IFN)
Description: 1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Study NCT01482767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Study NCT02718209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mid-Infrared Spectroscopy with ATR